Sidvim LifeSciences Private Limited

Summary of the blog post: 2-minute read.  API & IP Intelligence Roundup (07 September 2026) The latest regulatory intelligence highlights vital lifecycle formulation innovations via the USFDA 505(b)(2) pathway, strategic corporate realignments, and a precedential D.C. Circuit ruling overturning FDA's interpretation of 180-day generic exclusivity forfeiture . 1. Recent 505(b)(2) NDA Approvals & Filings (August 2026) The 505(b)(2) pathway continues to deliver differentiated clinical value, de-risking development by building on established reference molecules : Baxter Healthcare (Sodium Bicarbonate Injection, USP — NDA 218524): Approved in ready-to-administer (RTA) Viaflo plastic containers ( 150 mEq/1,000mL ) . This factory-standardised, isotonic continuous-infusion presentation eliminates manual cleanroom compounding from hypertonic 8.4% vials under USP <797>, reducing the risk of bedside calculation errors and acute hypernatremia in intensive care units . ...

Summary of this blog post: 5-minute read API & IP Intelligence Roundup (31 August 2026) This edition highlights major pipeline opportunities from the USFDA’s June 2026 Off-Patent, Off-Exclusivity (OPOE) list , key global regulatory compliance actions, and a major Hatch-Waxman patent ruling where Lupin defeated Vertex Pharmaceuticals over Kalydeco (ivacaftor) . 1. Niche Generic Pipeline: USFDA Releases Updated OPOE Drug List (June 2026) The USFDA published its biannual update to identify approved reference products that have no patent or regulatory exclusivity barriers and lack approved generic (ANDA) equivalents . Part I (Immediate Filing Opportunities): Lists 699 prescription products for which the Agency can immediately accept an ANDA without prior consultation . This includes 42 solid oral tablet products , such as: Oncology & Speciality: Chlorambucil (2 mg), Busulfan (2 mg), Mitotane (500 mg), and Hydroxyurea (100 mg) . Infectious Disease: Pivmecillinam HCl (Eq...